



# DURECT Corporation to Participate in Upcoming Healthcare Conferences

CUPERTINO, Calif., Nov. 7, 2011 /PRNewswire via COMTEX/ —

DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.

(Logo: <http://photos.prnewswire.com/prnh/20020717/DRRXLOGO>)

- Jim Brown, President and CEO, will present at the Credit Suisse Health Care Conference in Phoenix, Arizona on Wednesday, November 9 at 3:00 p.m. Pacific Time. A live audio webcast of the presentation will be available by accessing [http://cc.talkpoint.com/cred001/110911a\\_ah/?entity=74\\_KGNYQKK](http://cc.talkpoint.com/cred001/110911a_ah/?entity=74_KGNYQKK). If you are unable to participate during the live webcast, the call will be archived on DURECT's website ([www.durect.com](http://www.durect.com)) under Audio Archive in the "Investor Relations" section.
- Matt Hogan, Chief Financial Officer, will present at the Piper Jaffray Health Care Conference in New York on Tuesday, November 29 at 1:00 p.m. Eastern Time. A live audio webcast of the presentation will be available by accessing [http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=DRRX&item\\_id=4228861](http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=DRRX&item_id=4228861). If you are unable to participate during the live webcast, the call will be archived on DURECT's website ([www.durect.com](http://www.durect.com)) under Audio Archive in the "Investor Relations" section.

## About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR(TM), ELADUR®, and TRANSDUR®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit [www.durect.com](http://www.durect.com).

NOTE: POSIDUR(TM), SABER(TM), ORADUR®, TRANSDUR®, ELADUR(TM) and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation